Quantcast

Actos Lawsuit News: Bernstein Liebhard LLP Comments on Opening Statements in First Actos Bladder Cancer Trial

March 1, 2013

The Firm continues to evaluate potential Actos lawsuits on behalf of patients who developed bladder cancer, allegedly due to long-term use of Actos.

New York, New York (PRWEB) March 01, 2013

Bernstein Liebhard LLP is closely monitoring developments in the nation´s first trial involving an Actos bladder cancer lawsuit. According to Bloomberg.com, opening statements were presented in Los Angeles Superior Court yesterday, with a plaintiff´s attorney asserting that Takeda Pharmaceuticals failed to warn doctors of the cancer risk associated with Actos. Among other things, the jury was told that Takeda sales representatives visited the plaintiffs´ doctor 195 times to discuss its products, but never mentioned a bladder cancer risk associated with Actos. According to his Actos lawsuit, the plaintiff took the type 2 diabetes drug for four years before he was diagnosed with bladder cancer, and his prognosis is now terminal.*

“We continue to hear from long-term Actos users who developed bladder cancer while using this drug. Sadly, many of those individuals have stories similar to the plaintiff´s. We are pleased to see this trial get underway, as it may provide valuable insights into the way juries could rule in similar Actos lawsuits,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free lawsuit evaluations to individuals who were diagnosed with bladder cancer following long-term use of Actos.

Actos Bladder Cancer Lawsuits

Court records indicate that Takeda has been named in more than 3,000 Actos bladder cancer lawsuits, most of which are pending in a multidistrict litigation underway in U.S. District Court, Western District of Louisiana. That litigation´s first Pilot Bellwether trial will begin on January 27, 2014, while the second will commence on April 14, 2014. (In re: Actos Product Liability Litigation, MDL No. 2299) Court papers filed in the Actos lawsuit underway in Los Angeles show Takeda Pharmaceuticals secretly surveyed a dozen doctors in 2003 to see if they would use a diabetes drug with their patients that carried a warning about the potential for bladder cancer. Plaintiff´s attorneys assert the survey found that “a bladder cancer warning would destroy the sales of Takeda´s most important drug.”

In June 2011, the U.S. Food & Drug Administration (FDA) ordered Takeda to add new warnings to the Actos label, after a study found that long-term use of the drug increased the risk for bladder cancer.** Since the FDA issued its Actos bladder cancer alert, a number of other studies have confirmed an association between the drug and the disease. Most recently, a study published in the British Diabetic Association journal, “Diabetic Medicine,” found that the risk of bladder cancer was significantly higher in patients using Actos compared with control groups.*** Research published last May in the British Medical Journal concluded that taking the drug for two years can double the risk of developing bladder cancer. **** A second study published in the Canadian Medical Association Journal in July 2012 found that patients taking Actos face a 22 percent increased risk of developing bladder cancer. *****

Actos users who developed bladder cancer may be entitled to file an Actos lawsuit to obtain compensation for medical expenses, lost wages, pain and suffering, and more. Learn more about filing an Actos bladder cancer lawsuit by visiting Bernstein Liebhard LLP´s website, http://www.consumerinjurylawyers.com/. For additional information, contact a lawyer at Bernstein Liebhard LLP today at (877) 779-1414.

*bloomberg.com/news/2013-02-28/takeda-didn-t-warn-of-actos-cancer-risk-lawyer-says.html

** fda.gov/drugs/drugsafety/ucm259150.htm

***ncbi.nlm.nih.gov/pubmed/23350856

****bmj.com/content/344/bmj.e3645

*****health.usnews.com/health-news/news/articles/2012/07/03/another-study-links-diabetes-drug-actos-to-bladder-cancer

About Bernstein Liebhard LLP

Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs´ Hot List,” recognizing the top plaintiffs´ firms in the country, for the past 10 consecutive years.

Bernstein Liebhard LLP

10 East 40th Street

New York, New York 10016

(877) 779-1414

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

###

Contact Information:

Felecia L. Stern, Esq.

Bernstein Liebhard LLP

info(at)consumerinjurylawyers(dot)com

http://www.consumerinjurylawyers.com

For the original version on PRWeb visit: http://www.prweb.com/releases/prwebactos-lawsuit/actos-bladder-cancer/prweb10488873.htm


Source: prweb



comments powered by Disqus